Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects
Placebo-Controlled, Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043
연구 개요
상태
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
New York
-
New York, New York, 미국, 10019
- Clinilabs, Inc.
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Healthy subjects as determined by no clinically significant deviation from normal medical history, physical examination, ECGs and clinical laboratory determinations
- Body Mass Index (BMI) of 18 to 30 kg/m2, inclusive. BMI = weight (kg)/ [height (m)]2
- Normal Neurological Exam (LP subjects only: to rule out focal CNS lesions that would render LP unsafe)
- Men and women, ages 18 to 55 years, inclusive.
- Women who are not of childbearing potential (WOCBP) [ie, who are postmenopausal or surgically sterile] and men
- Women must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of investigational product.
- Women must not be breastfeeding
- Sexually active fertile men must use effective birth control if their partners are WOCBP throughout the study and for 90 days after last dose
Exclusion Criteria:
- Any significant acute or chronic medical illness
- Current or recent (within 3 months of study drug administration) gastrointestinal disease
- Any major surgery within 4 weeks of study drug administration
- Any gastrointestinal surgery that could impact upon the absorption of study drug
- Donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within 4 weeks of study drug administration
- Blood transfusion within 4 weeks of study drug administration
- Inability to tolerate oral medication
- Inability to be venipunctured and/or tolerate venous access
- Smoking more than 1 cigarette/cigar per week, within 3 months prior to screening
- Regular daily use of nicotine products or Varenicline (Chantix® or Champix®) within 3 months prior to screening
- Recent (within 6 months of study drug administration) drug or alcohol abuse as defined in Diagnostic and Statistical Manual of Mental Disorders (4th Edition) [DSM IV], Diagnostic Criteria for Drug and Alcohol Abuse
- History of cardiac arrhythmias, or palpitations associated with presyncope or syncope or history of unexplained syncope
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Panel 1:BMS-933043(2mg)/Placebo+Antacid Buffer Solution
BMS-933043 2 mg solution by mouth twice daily for 10 days OR Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days |
|
|
실험적: Panel 2:BMS-933043(5mg)/Placebo+Antacid Buffer Solution
BMS-933043 5 mg solution by mouth twice daily for 10 days OR Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days |
|
|
실험적: Panel 3:BMS-933043(10mg)/Placebo+Antacid Buffer Solution
BMS-933043 10 mg solution by mouth twice daily for 10 days OR Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days |
|
|
실험적: Panel 4:BMS-933043(25mg)/Placebo+Antacid Buffer Solution
BMS-933043 25 mg solution by mouth twice daily for 10 days OR Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days |
|
|
실험적: Panel 5:BMS-933043(50mg)/Placebo+Antacid Buffer Solution
BMS-933043 50 mg solution by mouth twice daily for 10 days OR Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days CSF sampling required |
|
|
실험적: Panel 6:BMS-933043(100mg)/Placebo+Antacid Buffer Solution
BMS-933043 100 mg solution by mouth twice daily for 10 days OR Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days |
|
|
실험적: Panel 7:BMS-933043(200mg)/Placebo+Antacid Buffer Solution
BMS-933043 200 mg solution by mouth twice daily for 10 days OR Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days |
|
|
실험적: Panel 8:BMS-933043(25mg)/Placebo+Antacid Buffer Predose
MAD Phase: Japanese Subjects. Cerebrospinal fluid (CSF) sampling not required BMS-933043 25 mg solution by mouth twice daily for 10 days OR Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days |
|
|
실험적: Panel 9:BMS-933043(200mg)/Placebo+Antacid Buffer Predose
Japanese Subjects. CSF sampling not required. BMS-933043 200 mg solution by mouth twice daily for 10 days OR Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days |
|
|
실험적: Panel 10:BMS-933043(350mg)/Placebo+Antacid Buffer Predose
BMS-933043 350 mg solution by mouth twice daily for 10 days OR Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days |
|
|
실험적: CSF Panel:BMS-933043(MTD)/Placebo+Antacid Buffer Predose
If Panel 5 does not run. CSF Sampling at steady state BMS-933043 maximum tolerated dose (MTD), solution by mouth twice daily for 10 days OR Placebo matching with BMS-933043 0 mg solution by mouth twice daily for 10 days Antacid Buffer Predose 150 mL solution by mouth twice daily for 10 days |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Safety and tolerability of multiple oral doses of BMS-933043 in healthy subjects measured by AEs, Vital signs, clinical laboratory test results, physical examination findings, neurological examination findings and electrocardiogram (ECG) parameters
기간: Up to Day 26 of Follow-up
|
AEs = Adverse Events
|
Up to Day 26 of Follow-up
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Maximum observed plasma concentration (Cmax)
기간: Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data
|
Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
|
Time of maximum observed plasma concentration (Tmax)
기간: Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data
|
Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
|
Area under the concentration-time curve in one dosing interval [AUC(TAU)]
기간: Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data
|
Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
|
Plasma half-life (T-HALF)
기간: Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data
|
Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
|
Trough observed plasma concentration (Cmin) between dose interval
기간: Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data
|
Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
|
Volume of distribution at steady-state (VSS/F) of BMS-933043
기간: Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
PK of BMS-933043 will be derived from plasma concentration versus time and urinary excretion data
|
Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
|
Accumulation index (AI): ratio of AUC(TAU) at steady-state to AUC(TAU) after the first dose
기간: Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data
|
Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
|
Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight [MR AUC(tau)]
기간: Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data
|
Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
|
Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight [MR Cmax]
기간: Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
PK of BMS-933043, BMS-941651, BMS-972869 and BMS-610999 will be derived from plasma concentration versus time and urinary excretion data
|
Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
|
CSF penetration of BMS-933043
기간: Day 8
|
Cerebral Spinal Fluid (CSF) will be analyzed for drug levels to confirm adequate central nervous system (CNS) penetration (>2 nM is required) and to estimate the brain/plasma ratio in humans
|
Day 8
|
|
Effect of BMS-933043 on ECG intervals and to explore the relationship between plasma exposure and ECG intervals
기간: Baseline (Day -2), Day 1, Day 6 and Day 10
|
The effects of BMS-933043 on ECG parameters (heart rate, QTcF, PR, and QRS) will be explored graphically and by summary statistics.
Absolute levels, as well as changes from baseline, will be summarized and plotted versus time by treatment and day for each ECG parameter.
Frequency distributions for subjects' maximum values will be provided by treatment.
The relationships between ECG parameters and BMS-933043 concentrations may be explored using scatter plots and the relationship between the change from baseline in QTcF and the BMS-933043 concentration may be estimated
|
Baseline (Day -2), Day 1, Day 6 and Day 10
|
|
Safety and tolerability of multiple oral doses of BMS-9333043 in Japanese healthy subjects is measured by AEs, Vital signs, clinical laboratory test results, physical examination findings, neurological examination findings and ECG parameters
기간: Up to 6 months
|
Up to 6 months
|
|
|
Effect of ethnicity (Japanese versus non-Japanese) on PK of BMS-933043 will be assessed graphically and by point estimates and 90% confidence intervals for geometric mean ratio for Cmax using data from subjects receiving the same dose of BMS-933043
기간: Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
Day 1, Day 3, Day 6, Day 9, Day 10, Day 11 and Day 12
|
공동 작업자 및 조사자
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CN171-002
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
Healthy Adult Normals에 대한 임상 시험
-
Vigil Neuroscience, Inc.모병ALSP미국, 캐나다, 독일, 네덜란드, 영국
-
Vigil Neuroscience, Inc.모집하지 않고 적극적으로ALSP미국, 프랑스, 독일, 네덜란드, 영국
-
Assistance Publique - Hôpitaux de Paris모병부신백질이영양증 | 부신척수신경병증 | 이색성 백질이영양증 | Axonal Spheroids와 Pigmented Glia를 동반한 Adult-Onset Leukoencephalopathy프랑스
BMS-933043에 대한 임상 시험
-
China National Center for Cardiovascular DiseasesPeking University People's Hospital; Beijing Chao Yang Hospital; Hebei Medical University...알려지지 않은
-
Bristol-Myers Squibb모병진행성 폐 섬유증중국, 미국, 일본, 대한민국, 헝가리, 캐나다, 아르헨티나, 호주, 오스트리아, 벨기에, 브라질, 칠레, 콜롬비아, 체코, 덴마크, 핀란드, 프랑스, 독일, 그리스, 인도, 아일랜드, 이탈리아, 멕시코, 네덜란드, 페루, 폴란드, 포르투갈, 스페인, 스위스, 대만, 칠면조, 영국, 이스라엘, 말레이시아, 푸에르토 리코, 태국
-
Bristol-Myers Squibb모병특발성 폐 섬유증중국, 대만, 미국, 호주, 일본, 영국, 대한민국, 이스라엘, 캐나다, 아르헨티나, 오스트리아, 벨기에, 브라질, 칠레, 콜롬비아, 체코, 덴마크, 핀란드, 프랑스, 독일, 그리스, 헝가리, 인도, 아일랜드, 이탈리아, 멕시코, 네덜란드, 페루, 폴란드, 포르투갈, 스페인, 스위스, 칠면조, 푸에르토 리코
-
Bristol-Myers Squibb완전한
-
Bristol-Myers Squibb모병낭창미국, 아르헨티나, 독일, 멕시코, 폴란드, 루마니아, 불가리아, 스페인
-
Hoffmann-La Roche완전한